Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SAT1 | P21673 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13822687 | 0.88 | CYP2C19 (0.58) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL5596629 | 0.86 | — | — | |
| SCHEMBL5246451 | 0.84 | TSHR (0.44) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL5596696 | 0.84 | — | — | |
| SCHEMBL15510951 | 0.81 | TSHR (0.62) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL14930298 | 0.81 | TSHR (0.55) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL5932726 | 0.81 | CYP2C19 (0.57) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL30875975 | 0.81 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL15442502 | 0.80 | CYP2C19 (0.60) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL15511439 | 0.79 | TSHR (0.59) | CYP2C19MEN1GLAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379598-B1 | UNSATURATED COMPOUNDS CONTAINING CARBAMATE TERMINAL GROUPS OR UREA TERMINAL GROUPS | BASF AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| US-6916854-B2 | Heat and/or light curable films or coatings comprising polyurethanes or polyureaurethane copolymers having storage stability, used as automobile paints | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20040097642-A1 | Unsaturated compounds containing carbamate terminal groups or urea terminal groups | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| EP-1379598-A1 | UNSATURATED COMPOUNDS CONTAINING CARBAMATE TERMINAL GROUPS OR UREA TERMINAL GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002086000-A1 | UNSATURATED COMPOUNDS CONTAINING CARBAMATE TERMINAL GROUPS OR UREA TERMINAL GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | CYP2C19 4112/4885MEN1 2341/4885GLA 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.